Skip to main content

Table 1 Baseline characteristics of enrolled HCC patients

From: Real-world efficiency of lenvatinib plus PD-1 blockades in advanced hepatocellular carcinoma: an exploration for expanded indications

Variable All patients Tumor occupation ≥50% Invasion with Vp4
Yes No Yes No
Sample size n = 84 n = 31 n = 53 n = 30 n = 54
Median age (range) 53 (25–78) 51 (29–78) 53 (25–72) 51 (29–78) 53 (25–78)
Sex
 Male 69 (82.1) 25 (80.6) 44 (83.0) 25 (83.3) 44 (81.5)
 Female 15 (17.9) 6 (19.4) 9 (17.0) 5 (16.7) 10 (18.5)
HBsAg
 Positive 71 (84.5) 26 (83.9) 45 (84.9) 28 (93.3) 43 (79.6)
 Negative 13 (15.5) 5 (16.1) 8 (15.1) 2 (6.7) 11 (20.4)
Child-Pugh class
 A 72 (85.7) 23 (74.2) 49 (92.5) 25 (83.3) 47 (87.0)
 B 12 (14.3) 8 (25.8) 4 (7.5) 5 (16.7) 7 (13.0)
BCLC stage
 B 15 (17.9) 4 (12.9) 11 (20.8) 0 (0.0) 15 (27.8)
 C 69 (82.1) 27 (87.1) 42 (79.2) 30 (100.0) 39 (72.2)
Extrahepatic metastasis
 Yes 42 (50.0) 13 (41.9) 29 (54.7) 12 (40.0) 30 (55.6)
 No 42 (50.0) 18 (58.1) 24 (45.3) 18 (60.0) 24 (44.4)
AFP level ≥ 400 μg/ml
 Yes 45 (53.6) 20 (64.5) 25 (47.2) 19 (63.3) 26 (48.1)
 No 39 (46.4) 11 (35.5) 28 (52.8) 11 (36.7) 28 (51.9)
Prior systemic treatment
 Yes 10 (11.9) 5 (16.1) 5 (9.4) 0 (0.0) 10 (18.5)
 No 74 (88.1) 26 (83.9) 48 (90.6) 30 (100.0) 44 (81.5)
Prior TACE
 Yes 33 (39.3) 9 (29.0) 24 (45.3) 8 (26.7) 25 (46.3)
 No 51 (60.7) 22 (71.0) 29 (54.7) 22 (73.3) 29 (53.7)
Maximum diameter of HCC ≥ 5 cm
 Yes 64 (76.2) 30 (96.8) 34 (64.2) 27 (90.0) 37 (68.5)
 No 20 (23.8) 1 (3.2) 19 (35.8) 3 (10.0) 17 (31.5)